ADVANCE

11.140 patients, 214 sites, finalised 2008                                                                               Together with the AACT partners, The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release (MR) Controlled Evaluation (ADVANCE) trial was performed. This phase III clinical trial was conducted in 214 collaborating centers in more than 20 countries worldwide.
The ADVANCE trial was designed to provide reliable evidence about benefits and risks conferred by routine blood pressure lowering therapy and intensive glucose control therapy in high-risk type 2 diabetic patients, irrespective of initial blood pressure or glucose levels. The primary endpoints were composites of major macrovascular and microvascular events, analysed jointly and separately by intention to treat.
After 6 weeks on open label perindopril-indapamide combination, eligible individuals were randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen or usual guidelines-based therapy.

 

The Julius Center coordinated the European part of the investigation. Commenced in June 2001, successful worldwide recruitment was completed in March 2003, with the inclusion of 11.140 high-risk individuals with type 2 diabetes.  

 

This trial is registered on ClinicalTrials.gov, number NCT00145925.

 

 

 

Recruitment rate over the years. Between brackets are the number of participants.

 

 

Publications:

de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, Cooper M, Grobbee DE, Hackett M, Hamet P, Heller SR, Lisheng L, Macmahon S, Mancia G, Neal B, Pan CY, Patel A, Poulter N, Travert F, Woodward M; ADVANCE Collaborative Group. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 2009;52(11):2328-36.

 

Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J; ADVANCE Collaborative Group, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009;32(11):2068-74.

 

Heller SR; ADVANCE Collaborative Group. A summary of the ADVANCE Trial. Diabetes Care 2009;32(2):357-61.

 

Kengne AP, Czernichow S, Huxley R, Grobbee D, Woodward M, Neal B, Zoungas S, Cooper M, Glasziou P, Hamet P, Harrap SB, Mancia G, Poulter N, Williams B, Chalmers J; ADVANCE Collaborative Group. Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 2009;54(2):399-404. 

 

Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, Lip GY, Patel A; ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30(9):1128-35.  

 

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59.

 

Chalmers J, Joshi R, Kengne AP, Ninomiya T, Bi Y, Bompoint S, Billot L, Patel A; ADVANCE Collaborative Group. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens Suppl. 2008;26(3):21-7.

 

Chalmers J, Joshi R, Kengne AP, Ninomiya T, Bi Y, Bompoint S, Billot L, Patel A; ADVANCE Collaborative Group. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens. 2008;26(3):23-30.

 

Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370(9590):829–40.

 

ADVANCE Collaborative Group. ADVANCE—Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med. 2005;22(7):882–888.